Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Punicalin

Punicalin
Contact us for more batch information
Select Batch
Purity:99.95%
Resource Download

Punicalin

Catalog No. T4S1718Cas No. 65995-64-4
Punicalin exerts anti-inflammatory, antioxidative, and anti-hepatotoxic activities, it shows inhibitory activity on HIV-1 reverse transcriptase in a dose-dependent manner, with an IC50 of 0.11 microg/ml (0.14 microM).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$43In Stock
5 mg$122In Stock
10 mg$198In Stock
25 mg$347In Stock
50 mg$516In Stock
100 mg$736In Stock
1 mL x 10 mM (in DMSO)$197In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Punicalin"

Product Introduction

Bioactivity
Description
Punicalin exerts anti-inflammatory, antioxidative, and anti-hepatotoxic activities, it shows inhibitory activity on HIV-1 reverse transcriptase in a dose-dependent manner, with an IC50 of 0.11 microg/ml (0.14 microM).
In vitro
The edema after carrageenan injection is believed to be biphasic in nature.?The initial phase, beginning 1 hr after carrageenan administration, is due to the release of histamine and serotonin.?The second phase occurs 2 to 5 hr after carrageenan administration.??is induced by the release of bradykinin, protease, prostaglandin and lysosome ?.?It has been reported that the second phase of edema is sensitive to most clinically effective anti-inflammatory agents, such as indomethacin.?However, that treatment with punicalagin and punicalin is effective against both phases of inflammation induced by carrageenan.
In vivo
Punicalagin and punicalin were the active components of T. catappa L., a hepatoprotective crude drug used in Southern Asia, and both found to exhibit great antioxidant activity and hepatoprotective effect on CC14- or acetaminophen-induced liver damages. Even if they had great antioxidant effects in smaller concentration in vitro, treatment with larger doses of punicalagin and punicalin yield liver cell damage in rats.?In studying their anti-inflammatory effects, similar results were also observed.
Animal Research
Edema in the left hind paw of rats was induced by injecting 0.05 ml of 1% (w/v) carrageenan into the limb.?Animals were divided into six groups with eight animals in each group.?The drug test groups were treated with 5 or 10 mg/kg body weight of each component 1 hr before carrageenan injection.?The animals in the control group received saline.?Another group of rats was administered 5 mg/kg indomethacin as a standard anti-inflammatory drug.
Chemical Properties
Molecular Weight782.53
FormulaC34H22O22
Cas No.65995-64-4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 25 mg/mL (31.95 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.2779 mL6.3895 mL12.7791 mL63.8953 mL
5 mM0.2556 mL1.2779 mL2.5558 mL12.7791 mL
10 mM0.1278 mL0.6390 mL1.2779 mL6.3895 mL
20 mM0.0639 mL0.3195 mL0.6390 mL3.1948 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords